Grass pollen allergy sublingual immunotherapy - ALK-Abello

Drug Profile

Grass pollen allergy sublingual immunotherapy - ALK-Abello

Alternative Names: Oralgen Grasspollen

Latest Information Update: 20 Jun 2014

Price : $50

At a glance

  • Originator Fornix BioSciences
  • Developer ALK-Abello
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Seasonal allergic rhinitis

Most Recent Events

  • 05 Apr 2011 Suspended - Preregistration for Seasonal allergic rhinitis in Netherlands (Sublingual)
  • 01 Jul 2010 ALK Abello acquires Artu Biologicals
  • 29 Apr 2010 Fornix completes enrolment in its phase III trial for Seasonal allergic rhinitis in Belgium, France, Germany, the Netherlands, Poland and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top